Cardinal Health Inc. ($CAH) Stock Forecast: Down 6.9% Today

What is Cardinal Health Inc.?

Cardinal Health (CAH) experienced a notable decline in the stock market today.

Why is Cardinal Health Inc. going down?

CAH stock is down 6.9% on Apr 30, 2026 16:51

• The stock dropped despite surpassing earnings expectations for the third quarter of 2026; however, revenue fell short of consensus estimates, leading to investor dissatisfaction.
• In the third quarter, the company showed strong performance with a 35% increase in non-GAAP diluted EPS and an 11% rise in revenue. Nonetheless, a 20% decrease in GAAP diluted EPS due to a goodwill impairment charge affected the overall perception.
• Despite an upward revision of its fiscal 2026 adjusted earnings and free cash flow guidance, the market responded unfavorably to the revenue miss, underscoring the significance of revenue performance in shaping investor outlook.
• The enhancement of Actinium-225 production capabilities in nuclear medicine might have been overshadowed by the revenue miss, contributing to the downward trend in Cardinal Health's stock.

CAH Price Chart

CAH Technical Analysis

CAH News

Why Is Cardinal Health Stock Sinking Thursday?

Cardinal Health's stock fell on Thursday despite beating earnings expectations for the third quarter of 2026, as the company's revenue missed consensus estimates. Despite this, Cardinal Health raised its fiscal 2026 adjusted earnings and free cash flow guidance, indicating confidence in its future performance and business resilience. The company also announced an expansion of its Actinium-225 production capabilities in nuclear medicine.

https://www.benzinga.com/markets/earnings/26/04/52178290/why-is-cardinal-health-stock-sinking-thursday

Earnings Flash (CAH) Cardinal Health, Inc. Posts Q3 Adjusted EPS $3.17 per Share, vs. FactSet Est of $2.79

Cardinal Health, Inc. (CAH) announced its Q3 adjusted Earnings Per Share (EPS) of $3.17, surpassing FactSet's estimate of $2.79. This financial update indicates the company's stronger-than-expected performance in the third quarter. The article also mentions recent analyst ratings and other related news for Cardinal Health.

https://www.marketscreener.com/news/earnings-flash-cah-cardinal-health-inc-posts-q3-adjusted-eps-3-17-per-share-vs-factset-est-of-ce7f58dbdf80f426

A Look At McKesson (MCK) Valuation After William Blair’s New Outperform Rating

William Blair has initiated coverage on McKesson (MCK) with an Outperform rating, highlighting confidence in the company's role in the U.S. drug distribution industry, following a recent dividend declaration of $0.82 per share. Despite a 4% decline in share price over the past month, McKesson has shown strong long-term shareholder returns. The article suggests McKesson is undervalued with a fair value pegged around $990.87, contrasting with its current trading price of $822.63, although potential risks from drug pricing policies and vertical integration are noted.

https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/a-look-at-mckesson-mck-valuation-after-william-blairs-new-ou

Cardinal Health (NYSE: CAH) lifts 2026 EPS outlook as non-GAAP Q3 profits surge

Cardinal Health reported robust third-quarter fiscal 2026 results, with non-GAAP diluted EPS soaring 35% to $3.17 and revenue increasing 11% to $60.9 billion. Despite a GAAP diluted EPS decline of 20% due to a $184 million goodwill impairment charge, the company raised its fiscal 2026 non-GAAP EPS outlook to $10.70-$10.80 and adjusted free cash flow guidance to $3.3-$3.7 billion, driven by strong operational performance and strategic capital allocation including debt reduction and share repurchases.

https://www.stocktitan.net/sec-filings/CAH/8-k-cardinal-health-inc-reports-material-event-32ec359a6b35.html

Cardinal: Fiscal Q3 Earnings Snapshot

Cardinal Health Inc. (CAH) reported fiscal third-quarter net income of $399 million, or $1.69 per share, with adjusted earnings of $3.17 per share, surpassing Wall Street expectations. However, the prescription drug distributor missed revenue forecasts, posting $60.94 billion against an expected $62.35 billion. The company anticipates full-year earnings between $10.70 and $10.80 per share, with its stock climbing 45% in the last 12 months.

https://www.kens5.com/article/syndication/associatedpress/cardinal-fiscal-q3-earnings-snapshot/616-5edb82ee-21e2-431c-997e-cd7e18db0575

Trending Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

XRP ($XRP) Crypto Forecast: Up 5.3% Today

Aave ($AAVE) Crypto Forecast: Up 5.3% Today

Cardinal Health Inc. Price History

22.03.2026 - CAH Stock was down 4.5%

• Cardinal Health (CAH) stock experienced a significant bearish movement, falling by 2.96%.
• Despite analysts' positive expectations for the earnings report, the market reacted negatively to the stock.
• The underperformance of CAH compared to competitors and broader market indices suggests that investors may have had higher expectations for the company's performance.
• The upcoming earnings report will be crucial in determining if the stock can regain its momentum and reverse the bearish trend.

05.00.2026 - CAH Stock was up 1.0%

• The strategic shift towards specialty pharmaceutical distribution and healthcare services by Cardinal Health is positively impacting its growth trajectory.
• The overall bullish sentiment in the pharmaceutical industry, as evidenced by the projected growth of the Palliative Care Market, is likely contributing to CAH's upward movement.
• Analysts lowering price targets for competitors like Cencora (COR) while maintaining a Neutral rating may be diverting investor attention towards Cardinal Health, driving its stock price higher.
• The recognition of Cardinal Health as a stable long-term investment due to its essential role in the healthcare supply chain and consistent demand for medications is attracting investors seeking steady growth opportunities.

02.11.2025 - CAH Stock was down 3.0%

• The bearish movement in Cardinal Health's stock today could be attributed to various factors:
• Despite the company's increased operating earnings, the recent revenue dip might have raised concerns among investors about its growth prospects.
• The acquisition announcement and year-end results reporting might have not met market expectations, leading to a negative sentiment towards the stock.
• The overall market sentiment towards healthcare stocks or specific developments within the healthcare sector could have influenced the bearish movement in CAH's stock price.
• Investors might be reevaluating Cardinal Health's financial stability and growth potential in comparison to other highlighted stocks with strong interest coverage ratios.
• The focus on financial metrics like the Price-to-Earnings ratio and valuation scores in discussions about other companies could have also shifted investor attention away from Cardinal Health, impacting its stock performance negatively.

13.00.2026 - CAH Stock was up 5.2%

• Following an upward trend, Cardinal Health's stock witnessed a surge subsequent to the company's revision of its fiscal-year guidance and its forecast of specialty revenue surpassing $50 billion for 2026.
• The optimistic projections for 2026, fueled by successful strategic moves like alterations in Medicare Drug Prices and alliances with Publix Super Markets, played a significant role in driving the stock's upward trajectory.
• Launches such as the ContinuCare™ Pathway program for diabetes supply management, coupled with strong performance across operational sectors, underscored the company's substantial strategic advancement.
• In essence, Cardinal Health's favorable forecasts and strategic endeavors have bolstered investors' confidence, thereby propelling the bullish trend in the stock market.

08.00.2026 - CAH Stock was down 3.0%

• The recent decline in CAH stock price could be linked to profit-taking by investors following a previous increase in value.
• Although Cardinal Health delivered impressive Q3 earnings that exceeded analyst expectations, market sentiment or profit-related concerns may have driven the stock lower.
• An increased investment by Robeco Institutional Asset Management B.V. initially inspired confidence in the stock, but prevailing market conditions may have overshadowed this development.
• Investor focus on the strong performance and growth potential of McKesson in the healthcare sector may have diverted attention from Cardinal Health, impacting its stock performance unfavorably.

05.01.2026 - CAH Stock was up 7.7%

• CAH surpassed analyst projections in its second-quarter earnings, leading to a rise in its stock value.
• The company adjusted its full-year earnings forecast upward for the second time, showing strong confidence in its future business performance.
• The robust results and achievement of a new 52-week high were driven by the strong performance in its Pharmaceutical and Specialty Solutions division.
• Investor sentiment towards CAH is optimistic, as analysts hold a consensus "Strong Buy" rating with potential for increased gains, reflecting confidence in the company's future growth.

05.01.2026 - CAH Stock was up 7.3%

• Today, Cardinal Health (CAH) witnessed a notable uptrend following the announcement of exceptional Q4 CY2025 results that outperformed market predictions.
• The company's strong financial showing was fueled by a substantial increase in revenue, surpassing analyst forecasts by a significant margin.
• Cardinal Health adjusted its full-year EPS guidance upwards, indicating optimism in its strategic efforts and the strong industry momentum in healthcare distribution.
• The upsurge in demand for specialty drugs and the company's foray into high-profit markets were key drivers in the positive outlook and the heightened profitability projections, further instilling investor confidence in Cardinal Health's future prospects.

05.01.2026 - CAH Stock was up 9.4%

• Cardinal Health's robust growth momentum, driven by strong utilization and successful acquisitions, has led to an impressive earnings report that surpassed analyst expectations.
• The company's consistent guidance hikes and increased fiscal-year earnings guidance have instilled confidence in investors, resulting in a surge in the stock price.
• Cardinal Health's focus on strategic initiatives and solid financial performance, including a significant increase in sales and adjusted earnings, has propelled the stock to reach a new 52-week high.
• The positive market sentiment towards Cardinal Health is further fueled by the CEO's explanation of the factors contributing to the company's success, reinforcing investor optimism in the stock's future prospects.

30.03.2026 - CAH Stock was down 5.6%

• Cardinal Health (CAH) reported strong third-quarter fiscal year 2026 results, with revenue increasing by 11% to $60.9 billion and non-GAAP diluted EPS rising by 35% to $3.17, but experienced a bearish market movement.
• The bearish movement followed the company missing revenue forecasts, posting $60.94 billion against an expected $62.35 billion, despite surpassing Wall Street's expectations for adjusted earnings.
• The market's response may have been influenced by the revenue miss overshadowing the positive earnings beat and the company's raised outlook for fiscal year 2026 non-GAAP EPS guidance to $10.70 to $10.80.
• Concerns about the revenue shortfall and potential risks like drug pricing policies and vertical integration challenges could have contributed to the bearish sentiment towards Cardinal Health's stock.

12.01.2026 - CAH Stock was down 3.8%

• Cardinal Health (CAH) faced a downwards trend in the market today amid mixed earnings reports in the healthcare sector.
• Despite positive Q4 results and an increased annual outlook, concerns emerged during the earnings call regarding profit distribution, capital management, and the effects of market price adjustments.
• A general sense of caution in the healthcare industry, exemplified by other companies like Baxter International and QuidelOrtho, may have influenced the negative response to Cardinal Health's performance.
• Investors appear to be reassessing their healthcare investments, resulting in a decline in CAH shares, despite the company's strong financial standing.

30.03.2026 - CAH Stock was down 6.9%

• The stock dropped despite surpassing earnings expectations for the third quarter of 2026; however, revenue fell short of consensus estimates, leading to investor dissatisfaction.
• In the third quarter, the company showed strong performance with a 35% increase in non-GAAP diluted EPS and an 11% rise in revenue. Nonetheless, a 20% decrease in GAAP diluted EPS due to a goodwill impairment charge affected the overall perception.
• Despite an upward revision of its fiscal 2026 adjusted earnings and free cash flow guidance, the market responded unfavorably to the revenue miss, underscoring the significance of revenue performance in shaping investor outlook.
• The enhancement of Actinium-225 production capabilities in nuclear medicine might have been overshadowed by the revenue miss, contributing to the downward trend in Cardinal Health's stock.

04.01.2026 - CAH Stock was down 5.0%

• Cardinal Health revised its FY25 earnings forecast upwards, anticipating notable growth in EPS over the next three years, which should typically have a positive effect on the stock.
• Allianz Asset Management GmbH decreased its ownership in Cardinal Health by 30%, potentially indicating investor uncertainty or profit-taking, which could have contributed to the recent market decline.
• Despite the encouraging earnings forecast and solid segment performance, the market's response towards Cardinal Health appears to have been more influenced by the significant reduction in ownership by a major investor, leading to the recent downturn.
• Various factors such as the overall healthcare sector's performance and general market trends may have also impacted the recent bearish movement of Cardinal Health's stock.